Edgestream Partners L.P. Takes Position in Roivant Sciences Ltd. $ROIV

Key Points

• Edgestream Partners acquired 40,807 shares of Roivant Sciences in the first quarter, worth approximately $1.13 million. Institutional investors now own 64.76% of the company.
• Analyst sentiment remains broadly positive: 10 analysts rate ROIV a Buy, one rates it Hold, and one rates it Sell. The consensus rating is “Moderate Buy,” with an average price target of $33.59.
• ROIV shares opened at $33.32, while company insiders sold more than 2.05 million shares worth approximately $69.6 million in the last quarter, including sizable sales by Director Melissa Epperly and CEO Eric Venker.

Edgestream Partners L.P. acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 40,807 shares of the company's stock, valued at approximately $1,130,000.

A number of other large investors have also recently bought and sold shares of ROIV. Goldman Sachs Group Inc. raised its holdings in Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock valued at $24,553,000 after buying an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock worth $24,678,000 after acquiring an additional 34,341 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock worth $1,010,000 after acquiring an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock valued at $129,000 after acquiring an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company's stock valued at $144,000 after acquiring an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ROIV has been the subject of several analyst reports. TD Cowen boosted their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a "buy" rating in a report on Thursday, May 21st. Guggenheim increased their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, May 26th. Bank of America reiterated a "neutral" rating on shares of Roivant Sciences in a report on Friday. Weiss Ratings lowered shares of Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, May 22nd. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.59.

Roivant Sciences Stock Down 1.7%

Shares of ROIV opened at $33.32 on Tuesday. The stock's 50-day moving average price is $32.70 and its 200 day moving average price is $29.17. The firm has a market capitalization of $23.97 billion, a price-to-earnings ratio of -55.53 and a beta of 1.12. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00.

Insider Transactions at Roivant Sciences

In related news, Director Melissa B. Epperly sold 17,750 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the transaction, the director directly owned 16,474 shares in the company, valued at approximately $566,376.12. This represents a 51.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares of the company's stock, valued at approximately $56,376,551.85. This trade represents a 11.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 2,055,913 shares of company stock valued at $69,639,633. 8.80% of the stock is owned by corporate insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.